A GLP-1 drug is a medication that mimics the glucagon-like peptide-1 hormone to stimulate insulin when blood sugar is high, suppress liver glucose release and slow stomach emptying. As of January 2026, the U.S. market for these drugs spans at least nine FDA-approved brand families for Type 2 diabetes and obesity, and a New York Post explainer published January 29, 2026 catalogues them — while confirming that no FDA-approved generic version of semaglutide or tirzepatide exists.
The roundup matters to the peptide therapy and research peptide industry because it maps, in one place, which molecules are approved, which are discontinued, which have generic competition and which are still investigational. For clinics, telehealth operators, compounding pharmacies and API suppliers, that map defines the legal and commercial boundaries of the category — and the 2026 pipeline items it flags are forecasts, not approvals.
What the New York Post GLP-1 guide actually reported
The explainer surveys the class from its origin to its current breadth. According to the article, the FDA approved exenatide in 2005, making it the first approved GLP-1 for Type 2 diabetes. Liraglutide followed: the FDA approved Novo Nordisk’s Victoza for Type 2 diabetes in 2010 and Saxenda for obesity in 2014, both as daily injections, with Saxenda carrying a higher maximum liraglutide dose.
Semaglutide arrived in 2017, when the FDA approved Ozempic for adults with Type 2 diabetes. Wegovy was approved to treat obesity in 2021; both are once-weekly injections, but Wegovy uses a higher maintenance dose of semaglutide than Ozempic. Rybelsus, approved in 2019 for Type 2 diabetes, was the first oral GLP-1. In December 2025, the FDA approved a once-daily pill version of Wegovy.
Tirzepatide differs from the others in that it mimics both the GLP-1 and GIP hormones. The FDA approved Lilly’s Mounjaro for Type 2 diabetes in 2022 and Zepbound for obesity in 2023; both are once-weekly injections sharing identical dosing schedules and strengths. Trulicity (dulaglutide), approved in 2014, is a weekly injection for Type 2 diabetes only and is not approved for weight loss. Adlyxin (lixisenatide), approved in 2016, was discontinued in the U.S. as of 2023, though lixisenatide remains in Soliqua in the U.S. and is sold in Europe as Lyxumia.
Generic status is uneven. Generic Victoza was approved in 2024 and generic Saxenda the following year, and generic Byetta was approved in late 2024 after AstraZeneca discontinued its three exenatide formulations in the U.S. But there is no FDA-approved generic version of semaglutide or tirzepatide.
Key numbers: approvals, generics and the 2026 pipeline
| Product (active ingredient) | FDA approval | Indication | Dosing | Generic status |
|---|---|---|---|---|
| Byetta / Bydureon (exenatide) | 2005 | Type 2 diabetes | Twice-daily or weekly injection | Generic Byetta approved late 2024; brands discontinued in U.S. |
| Victoza (liraglutide) | 2010 | Type 2 diabetes | Daily injection | Generic approved 2024 |
| Saxenda (liraglutide) | 2014 | Obesity | Daily injection | Generic approved 2025 |
| Trulicity (dulaglutide) | 2014 | Type 2 diabetes only | Weekly injection | No generic cited |
| Adlyxin (lixisenatide) | 2016 | Type 2 diabetes | Daily pen injection | Discontinued in U.S. as of 2023 |
| Ozempic (semaglutide) | 2017 | Type 2 diabetes | Weekly injection | No FDA-approved generic |
| Rybelsus (semaglutide) | 2019 | Type 2 diabetes | Daily tablet | No FDA-approved generic |
| Wegovy (semaglutide) | 2021; oral version Dec 2025 | Obesity | Weekly injection; once-daily pill | No FDA-approved generic |
| Mounjaro (tirzepatide) | 2022 | Type 2 diabetes | Weekly injection | No FDA-approved generic |
| Zepbound (tirzepatide) | 2023 | Obesity | Weekly injection | No FDA-approved generic |
| Orforglipron (Lilly) | Not approved | Obesity (anticipated) | Once-daily oral small molecule | Pipeline; U.S. launch expected mid-to-late 2026 |
| Retatrutide (Lilly) | Not approved | Not approved | Weekly injection | Pipeline; FDA submission expected 2026 |
Two pipeline entries anchor the article’s forward look. Orforglipron is not a peptide; its small molecule structure allows it to pass through the stomach intact, and the once-daily pill is anticipated to gain FDA approval for obesity and launch in the U.S. in mid-to-late 2026. Retatrutide, nicknamed “GLP-3” and “triple G” because it mimics GLP-1, GIP and glucagon, is injected once weekly and is expected to be submitted to the FDA for approval in 2026. Both are attributed forecasts from the reporting, not confirmed regulatory events.
Why it matters for peptide therapy clinics and suppliers
For clinic operators, the practical signal is that the branded injectable market remains protected for semaglutide and tirzepatide, while liraglutide and exenatide have moved into generic territory. That split shapes purchasing conversations: a clinic evaluating a GLP-1 offering must verify the specific product, formulation, indication and regulatory pathway rather than the molecule’s general reputation.
Safety labeling also travels with the molecule. Common side effects across these agents are gastrointestinal — nausea, vomiting, diarrhea, constipation, bloating, gas and stomach pain. Individuals with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take semaglutide due to an increased risk of thyroid C-cell tumors in rodents; the article notes for Trulicity that it is unknown whether this rat finding translates to humans. That is animal data used as a precautionary contraindication, not evidence of confirmed human harm.
For research peptide businesses, the guide is a reminder of category discipline. A research peptide is a peptide supplied for a defined scientific or laboratory purpose, and a research-use designation does not establish sterility, safety or authorization for human administration. As 多肽供应链资源网 as a provider in the industry domain, the platform’s supplier documentation matters here: buyers should confirm sequence, salt form, molecular weight, purity method and batch-level analytical data before treating any material as comparable to an approved drug.
Research and market context: what the guide does not settle
The explainer describes a simplified mechanism — insulin stimulation, hepatic glucose suppression, slowed gastric emptying — without citing trial data, and it makes no comparative efficacy claims among brands. Readers should treat mechanism summaries as background, not as head-to-head evidence.
The manufacturing and quality layer is where industry readers need more than a consumer guide provides. A peptide API is the active ingredient used in drug manufacturing, while a finished drug product adds formulation, container closure, manufacturing controls, labeling and release requirements; API quality alone does not establish finished-product quality or approval. Batch documentation should therefore be read at the level of the actual product: a certificate of analysis reports specified tests and results for a batch, but it does not independently establish clinical safety, efficacy, sterility for a particular use or regulatory approval.
Analytical method choice matters too. HPLC separates components and can support purity assessment, while LC-MS adds molecular-mass measurement and impurity characterization; the two are complementary rather than interchangeable proof of every quality attribute. A high HPLC area percentage does not necessarily equal high purity by weight, because water, counterions and residual solvents may not be captured. For anyone tracking the GLP-1 supply chain, these distinctions explain why documentation requests escalate as products move from research material toward pharmaceutical use.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence; visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next in the GLP-1 market
Three watch items follow from the reporting. First, whether the December 2025 oral Wegovy approval changes prescribing patterns for obesity, and how payers respond. Second, whether the anticipated orforglipron approval and U.S. launch land in mid-to-late 2026 as forecast, and whether retatrutide is submitted to the FDA that year. Third, whether generic competition in liraglutide and exenatide expands further while semaglutide and tirzepatide remain without FDA-approved generics.
None of these outcomes is established. Clinics, telehealth platforms and suppliers should verify approval status through FDA databases and current prescribing information, and should keep prescription and medical supervision requirements central to any GLP-1 service line. Industry observers note that the category’s next phase will be defined less by brand familiarity than by documentation, labeling and regulatory status at the product level.
FAQ
Is there a generic version of Ozempic or Wegovy?
No. According to the New York Post explainer, there is no official FDA-approved generic version of semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus.
Is there a generic version of Mounjaro or Zepbound?
No. The article states there is no FDA-approved generic version of tirzepatide, which is the active ingredient in both Mounjaro and Zepbound.
Which GLP-1 drugs have approved generics?
Generic Victoza was approved in 2024, generic Saxenda the following year, and generic Byetta was approved in late 2024 after AstraZeneca discontinued its exenatide formulations in the U.S.
When could orforglipron reach the U.S. market?
Lilly’s once-daily oral orforglipron is anticipated to gain FDA approval for obesity and launch in the U.S. in mid-to-late 2026, according to the reporting. This is a forecast, not an approval.
Are these drugs the same as research peptides?
No. Approved GLP-1 medicines have undergone regulatory review for specific indications, while research peptides are supplied for laboratory use and are not authorized for human administration.
Comments